

Effect of gene environment interactions on lung function and cardiovascular disease in COPD

Tillie-Louise Hackett^{1,2,*}
Dorota Stefanowicz^{1,*}
Farzian Aminuddin¹
Don D Sin¹
John E Connett³
Nicholas R Anthonisen⁴
Peter D Paré¹
Andrew J Sandford¹

¹University of British Columbia, James Hogg Research Laboratories, St Paul's Hospital, Division of Respiratory, Department of Medicine, ²Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, BC, Canada; ³School of Public Health, University of Minnesota, Minneapolis, MN, USA; ⁴Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada

*These authors contributed equally to this work

Background: The objective of this study was to determine if gene-environment interactions between cigarette smoking and interleukin-6 (*IL6*), interferon- γ (*IFNG*), interleukin-1 β (*IL1B*), or interleukin-1 receptor antagonist (*IL1RN*) single nucleotide polymorphisms are associated with lung function decline and cardiovascular disease in chronic obstructive pulmonary disease (COPD).

Methods: Single nucleotide polymorphisms (SNPs) in *IL6*, *IFNG*, *IL1B*, and *IL1RN* were genotyped in the Lung Health Study and correlated with rate of decline of forced expiratory volume in 1 second (FEV₁) over 5 years, baseline FEV₁, serum protein levels, cardiovascular disease, and interactions with smoking.

Results: The *IL6* rs2069825 single nucleotide polymorphism was associated with the rate of decline of prebronchodilator FEV₁ ($P = 0.049$), and was found to have a significant interaction ($P = 0.004$) with mean number of cigarettes smoked per day. There was also a significant interaction of *IFNG* rs2069727 with smoking on prebronchodilator ($P = 0.008$) and postbronchodilator ($P = 0.01$) FEV₁. The *IL6* polymorphism was also associated with cardiovascular disease in heterozygous individuals ($P = 0.044$), and was found to have a significant interaction with smoking ($P = 0.024$). None of the genetic variants were associated with their respective serum protein levels.

Conclusion: The results suggest interactions of *IL6* rs2069825 and *IFNG* rs2069727 single nucleotide polymorphisms with cigarette smoking on measures of lung function. The *IL6* rs2069825 single nucleotide polymorphism also interacted with smoking to affect the risk of cardiovascular disease in COPD patients.

Keywords: gene-environment interactions, interleukin-6, forced expiratory volume in one second, cardiovascular disease, chronic obstructive pulmonary disease

Introduction

Cigarette smoking is responsible for nearly five million deaths annually, with the leading cause of tobacco-related mortality being cardiovascular disease, followed by chronic obstructive pulmonary disease (COPD).¹ While the adverse effects of cigarette smoking on lung health and “systemic” diseases are well established, the precise mechanism by which cigarette smoke mediates its systemic effects needs to be clarified. Due to the large variation in the adverse effects of cigarette smoke, it has been proposed that other factors, such as gene-environment interactions, may be important in promoting tobacco-related disease.^{2,3} COPD represents a clear example of gene-environment interactions because although cigarette smoking is the main environmental trigger for COPD in developed countries, considerable variation exists in disease outcomes, which are likely related to an individual's genetic load.

Correspondence: Andrew Sandford
UBC James Hogg Research Centre
at the Heart and Lung Institute,
St Paul's Hospital, 1081 Burrard Street,
Vancouver, BC, Canada V6Z 1Y6
Tel +1 604 806 8346
Fax +1 604 806 8351
Email andrew.sandford@hli.ubc.ca

Pulmonary inflammation is central to the development of COPD, characterized by increased numbers of neutrophils, macrophages, and lymphocytes, leading to the destruction of lung parenchyma, goblet cell hypertrophy, and tissue remodeling. In some patients, COPD is associated with systemic effects, which include cachexia, skeletal muscle wasting, and increased comorbidities, such as cardiovascular disease.⁴ These systemic effects may be caused or sustained by the enhanced systemic inflammation observed in some COPD patients.

Due to the complexity of the inflammatory mediators released by immune cells in response to smoking, multiple mediators have been suggested to be involved in the progression of COPD. We have previously demonstrated the association between interleukin-6 (*IL6*), interferon- γ (*IFNG*), interleukin-1 β (*IL1B*), and interleukin-1 receptor antagonist (*IL1RN*) polymorphisms and a rapid decline or baseline level of lung function in smokers.⁵⁻⁷ The Lung Health Study (LHS) is a multicenter community-based cohort of smokers with mild to moderate airflow limitation.⁸ Our previous studies utilized a subset of individuals from the LHS cohort to form a nested case-control study based on the extremes of distribution for the rate of decline in lung function and baseline lung function.⁵⁻⁷ Our rationale in this study was to investigate if gene \times smoking interactions were associated with lung function decline in the entire LHS cohort. This approach would therefore allow us to estimate the effect of the identified polymorphisms and interactions with smoking on continuous measures of lung function, rather than dichotomous extremes, which the previous subset analyses were underpowered to perform. Our second aim was to determine whether the genetic variants and/or gene \times smoking interactions were predictors of cardiovascular disease. We hypothesized that the link between COPD and mortality from cardiovascular disease is inflammation, through both local and systemic mechanisms.

Methods

LHS participants

The details of the LHS cohort have previously been published.⁸ Briefly, 5887 subjects who were cigarette smokers, aged 35–60 years, with mild to moderate airflow obstruction were recruited into the LHS cohort. Airflow obstruction was defined by a forced expiratory volume in one second (FEV_1) to forced vital capacity (FVC) ratio of ≤ 0.70 and FEV_1 55%–90% of predicted. Lung function measurements were performed annually over the 5 years of the study using

standardized spirometry, with quality control in accordance with the American Thoracic Society guidelines.^{9,10} During the follow-up phase of the study, the vital status of the participants was captured every 6 months. An independent mortality and morbidity committee reviewed death certificates, autopsy reports, and relevant hospital records to assign the causes of death for all participants who died during the study and confirmed data by linkage with the US National Death Index.¹¹

On recruitment into the LHS cohort, each individual's smoking history was recorded in pack-years. At each subsequent annual visit, the smoking status of each participant was ascertained based on self-reporting and was objectively verified by determining cotinine levels in saliva samples and/or carbon monoxide concentrations in expired air (Minico, Catalyst Research or EC50, Vitalograph). Participants were categorized as continued smokers or sustained quitters based on self-reporting and a validated biochemical measurement at all five follow-up visits.⁸

Individuals who had a history of cancer (except carcinoma in situ or basal cell carcinoma of the skin), myocardial infarction (in the past 2 years), angina, heart failure, stroke (in the past 2 years), renal failure, insulin-requiring diabetes mellitus, cirrhosis or other serious liver disease, pulmonary embolism, disorders of the central nervous system, narrow-angle glaucoma, or any other major diseases which could have compromised follow-up, were excluded from the cohort.

Polymorphism selection and genotyping methods

Four single nucleotide polymorphisms (SNPs) were selected because they showed significant associations with either rate of decline or baseline lung function in our previous nested case-control studies of the LHS cohort.⁵⁻⁷ In addition, the respective proteins have previously been implicated in the pathogenesis of cardiovascular disease.¹²⁻¹⁷ Genotyping was performed using the TaqMan method (Applied Biosystems, Foster City, CA).

Serum *IL6*, *IL1 β* , *IL1RN*, and *IFNG* concentrations

At the fifth annual visit, DNA and serum was isolated using venipuncture. The serum samples were stored at -70°C and used to measure the concentrations of *IL6*, *IL1 β* , *IL1RN*, and *IFNG* using a highly sensitive chemiluminescent multiplexed sandwich immunoassay (SearchLight Proteome Array System, Rockford, IL).

Statistical analysis

Hardy–Weinberg equilibrium was assessed using χ^2 goodness-of-fit tests, and linkage disequilibrium estimations were performed using the CubeX cubic exact solutions program.¹⁸ Multivariate linear regressions for prebronchodilator and postbronchodilator rate of decline were performed to test for associations with each SNP. The confounding factors included for these analyses were age, body mass index, smoking status (continuous versus noncontinuous), and mean number of cigarettes smoked per day during the LHS follow-up period.

Multivariate linear regressions for baseline FEV₁% predicted were performed to test for associations with each SNP. Confounding factors included for analyses of baseline lung function were age, body mass index, and pack-years of smoking. Pack-years of smoking was used as the covariate because this smoking measure was thought to be the most representative of patient smoking history prior to the start of the study.

Multivariate logistic regressions were used to test for the association of each SNP with cardiovascular disease and fatal cardiovascular disease.

Multivariate linear regressions were also performed to test for association of each SNP with logarithmically transformed serum levels of their respective proteins, with age, body mass index, and pack-years of smoking included as covariates.

Rate of decline in lung function was determined by the difference between lung function at the start and end of the study divided by the number of years between the two measurements. Gene \times smoking interactions were tested in the entire LHS cohort by adding a multiplicative term to the regression models.

The single locus analyses described above were performed using the JMP statistical package (SAS Institute Inc, Cary, NC). Haplotype analysis was done using the SimHap package.¹⁹ If we were to apply a Bonferroni correction for the total number of 29 comparisons conducted in this study, there would be no association that would survive this stringent level of correction. Because many of the phenotypes and the *IL1B* and *IL1RN* SNPs tested were significantly associated, we used a matrix spectral decomposition approach to estimate the effective number of independent phenotypes and genotypes.²⁰ Using the matrix spectral decomposition approach, the total effective number of variables (V_{eff}) tested for *IL6*, *IFNG*, *IL1B*, and *IL1RN* was 8.15, 7.25, 9, and 9, respectively. The significance threshold required to keep the Type I error rate at 5% ($0.05/V_{\text{eff}}$) for *IL6*, *IFNG*, *IL1B*, and *IL1RN* was 6.137×10^{-3} , 6.894×10^{-3} , 5.555×10^{-3} , and 5.555×10^{-3} , respectively, for each gene.

Results

Characteristics of study participants

Of the 5887 LHS participants, 4189 had DNA and complete phenotypic data available. Of those, 4036 (96%) were of European descent and were utilized in the subsequent analyses because we had insufficient power to study the other ethnic groups. The total cohort (n = 4036) was used to investigate gene \times smoking interactions on lung function, the effects of polymorphisms on serum levels of their respective proteins, and the influence of genetic variants on cardiovascular disease. The subset of LHS participants (n = 2523) that had not been previously included in genetic studies of these polymorphisms was used to investigate associations with lung function measures. The demographic characteristics of the LHS participants are shown in Table 1.

Table 1 Distribution of demographic characteristics for participants in the Lung Health Study

	Total cohort (N = 4036)	Subset ^a (N = 2523)
Gender (F/M)	1479/2557	925/1598
Age (years)	48.51 (6.74)	48.54 (6.69)
Smoking history (pack years ^b)	40.26 (18.29)	40.36 (18.12)
Mean cigarettes/day ^c	15.09 (13.55)	13.97 (13.69)
Smoking status during 5-year follow-up ^d		
Continuing smokers	2177	1169
Intermittent quitters	1148	833
Sustained quitters	711	521
BMI (kg/m ²)	25.52 (3.83)	25.56 (3.84)
Baseline FEV ₁ (% predicted pre-BD) ^e	75.41 (8.87)	76.18 (6.57)
Baseline FEV ₁ (% predicted post-BD) ^f	78.55 (9.20)	79.16 (5.88)
Δ FEV ₁ /year (% predicted pre-BD) ^g	-0.83 (1.67)	-0.72 (1.37)
Δ FEV ₁ /year (% predicted post-BD) ^h	-0.64 (1.57)	-0.51 (1.36)
Median (IQR) IL6 (pg/mL)	2.6 (1.8–4.3)	NA
Median (IQR) IFN γ (pg/mL)	6.1 (3.4–14.2)	NA
Median (IQR) IL1RN (pg/mL)	138 (96–198)	NA
Median (IQR) IL1 β (pg/mL)	1.27 (0.79–2.44)	NA
Cardiovascular disease death (yes/no)	71/3965	NA
Cardiovascular disease (yes/no)	705/3331	NA

Notes: ^aExcluding participants in previous studies; ^bNumber of packs of cigarettes smoked per day times number of years smoking; ^cNumber of cigarettes smoked per day during 5-year follow-up; ^dContinuing smokers: participants who reported smoking at each annual visit. Sustained quitters: participants who were validated by salivary cotinine or exhaled carbon monoxide levels as abstinent at every annual visit. Intermittent quitters: participants who were not sustained quitters or continuing smokers; ^eLung function at the start of the LHS measured as FEV₁ % predicted pre-bronchodilator; ^fLung function at the start of the LHS measured as FEV₁ % predicted post-bronchodilator; ^gChange in lung function per year over a 5-year period as % predicted FEV₁ pre-bronchodilator; ^hChange in lung function per year over a 5-year period as % predicted FEV₁ post-bronchodilator. Values are means \pm SD for continuous data unless otherwise stated.

Abbreviations: BD, bronchodilator; BMI, body mass index; FEV₁, forced expiratory volume in 1 second; IL6, interleukin-6; IFN γ , interferon gamma; IL1RN, interleukin 1 receptor antagonist; IL1 β , interleukin-1 β ; IQR, interquartile range.

Polymorphism genotyping assays, linkage disequilibrium, and Hardy–Weinberg equilibrium

In our previous study of *IL1B* and *IL1RN* polymorphisms, we genotyped a variable number of tandem repeats in intron 2 of the *IL1RN* gene.⁷ In order to facilitate rapid genotyping of the large number of samples in this study, we utilized a SNP (rs419598) that was reported to be in high linkage disequilibrium with the tandem repeat polymorphism.²¹ We confirmed this association in a sample of 571 LHS participants for whom we had genotypic information for both polymorphisms. The linkage disequilibrium statistic between the tandem repeat (considering alleles A1 and A2) and rs419598 in these individuals was $r^2 = 0.97$.

We genotyped the LHS participants for four polymorphisms, ie, rs2069825 in *IL6*, rs2069727 in *IFNG*, rs16944 in *IL1B*, and rs419598 in *IL1RN*. In the total of 4032 individuals, genotyping success rates were in the range of 91.8%–96.2%. The frequencies of the SNP alleles and genotypes are listed in Table 2. All SNPs were in Hardy–Weinberg equilibrium in all groups, except for *IL6* rs2069825, for which there was a slight excess of heterozygotes ($P = 0.02$).

Analysis of rate of decline and baseline FEV₁

We analyzed each polymorphism for association with rate of decline of prebronchodilator and postbronchodilator FEV₁ in the LHS participants not previously studied for these variants. In contrast with our previous studies,^{5,6} there was no association of any polymorphism with the rate of decline of lung function (Table 3). Similarly, there was no association of the polymorphisms with measures of baseline lung function in the same subset of individuals (Table 3). However, when we analyzed the entire LHS cohort ($P = 0.0486$) and the original subset of patients ($P = 0.0063$) we did find a significant effect of the *IL6* rs2069825 SNP on the rate of decline of prebronchodilator FEV₁ (Table 4).

We had previously found a significant association of *IL1B* and *IL1RN* haplotypes with rate of decline of lung function.⁷ Therefore, we tested haplotypes of the rs16944 and rs419598 polymorphisms in the LHS cohort not previously tested. Contrary to our previous results, none of the haplotypes were associated with the rate of decline of lung function or with baseline lung function. When we analyzed the entire LHS cohort, we also found no significant associations except with the original subset analysis (data not shown).

Analysis of gene × smoking interactions

We investigated gene × smoking interactions in the entire LHS cohort. The data in Table 4 suggested a recessive effect of the *IL6* rs2069825 SNP and therefore interactions of this polymorphism were explored in a recessive model. We found a significant interaction ($P = 0.0044$) of the *IL6* rs2069825 SNP with mean number of cigarettes smoked per day on rate of decline of prebronchodilator FEV₁ (Table 5) which remained significant after corrections for multiple comparisons by gene ($P = 0.0359$). This interaction is illustrated in Figure 1, which shows a faster rate of decline in individuals with the *IL6* rs2069825 [–/–] genotype. There was also a significant overall interaction of *IFNG* rs2069727 with smoking on prebronchodilator ($P = 0.0098$) and postbronchodilator ($P = 0.0077$) FEV₁ (Table 5). There were no significant gene × smoking interactions on lung function parameters with the other polymorphisms studied.

Analysis of serum protein levels

We determined whether each of the four polymorphisms was associated with the serum level of its respective protein. However, none of the genetic variants was significantly associated with the protein levels of IL6, IL1β, IL1RN, or IFNγ measured in peripheral blood ($P = 0.176$ – 0.599).

Table 2 Frequency of SNP alleles and genotypes in the total cohort (n = 4036)

Gene	SNP	Alleles ^a	Chromosomal location ^b	Position in gene	Minor allele frequency (%)	Genotype frequency (%)		
						AA	AB	BB
IL6	rs2069825	CT/–	7: 22765341–22765342	Promoter	39	38	46	16
IFNG	rs2069727	A/G	12: 68548223	3' region	47	29	49	22
IL1RN	rs419598	T/C	2: 113887207	Exon 3	27	53	39	8
IL1B	rs16944	C/T	2: 113594867	Promoter	33	45	44	11

Notes: ^aThe first allele is the major allele, the second is the minor allele; ^bChromosome: base position (NCBI Build 37.1).

Table 3 Analysis of rate of decline and baseline of FEV₁ in the LHS subset not previously studied

Gene	Polymorphism	Genotype ^a	β (% predicted/year)	SE	P value
Rate of decline of pre-bronchodilator FEV₁					
IL6	rs2069825	CT/CT	–	–	–
		–/CT	–0.0404	0.0369	0.2733
		–/–	0.0378	0.0475	0.4267
IFNG	rs2069727	A/A	–	–	–
		A/G	0.0178	0.0354	0.6142
		G/G	–0.0078	0.0425	0.8540
IL1RN	rs419598	T/T	–	–	–
		C/T	0.0351	0.0438	0.4228
		C/C	–0.0462	0.0644	0.4728
IL1B	rs16944	C/C	–	–	–
		C/T	0.0333	0.0387	0.3897
		T/T	–0.0477	0.0535	0.3729
Rate of decline of post-bronchodilator FEV₁					
IL6	rs2069825	CT/CT	–	–	–
		–/CT	–0.0632	0.0358	0.0776
		–/–	0.0218	0.0462	0.6366
IFNG	rs2069727	A/A	–	–	–
		A/G	0.0150	0.0343	0.6605
		G/G	–0.0198	0.0412	0.6306
IL1RN	rs419598	T/T	–	–	–
		C/T	–0.0239	0.0425	0.5736
		C/C	0.0095	0.0626	0.8787
IL1B	rs16944	C/C	–	–	–
		C/T	0.0394	0.0377	0.2951
		T/T	–0.0408	0.0520	0.4321
Baseline level of pre-bronchodilator FEV₁					
IL6	rs2069825	CT/CT	–	–	–
		–/CT	–0.0300	0.1853	0.8712
		–/–	–0.2074	0.2390	0.3856
IFNG	rs2069727	A/A	–	–	–
		A/G	–0.1192	0.1794	0.5064
		G/G	0.2640	0.2154	0.2205
IL1RN	rs419598	T/T	–	–	–
		C/T	–0.3209	0.2217	0.1478
		C/C	0.3707	0.3264	0.2562
IL1B	rs16944	C/C	–	–	–
		C/T	–0.1483	0.1958	0.4487
		T/T	0.0501	0.2702	0.8528
Baseline level of post-bronchodilator FEV₁					
IL6	rs2069825	CT/CT	–	–	–
		–/CT	–0.0262	0.1659	0.8747
		–/–	–0.2546	0.2139	0.2342
IFNG	rs2069727	A/A	–	–	–
		A/G	–0.1650	0.1606	0.3043
		G/G	0.3989	0.1928	0.0386
IL1RN	rs419598	T/T	–	–	–
		C/T	–0.2209	0.1980	0.2649
		C/C	0.1958	0.2917	0.5021
IL1B	rs16944	C/C	–	–	–
		C/T	–0.2444	0.1749	0.1625
		T/T	0.0098	0.2415	0.9677

Notes: ^aThe first allele is the major allele, the second is the minor allele.

Abbreviations: FEV₁, forced expiratory volume in 1 second; IFN γ , interferon gamma; IL1RN, interleukin 1 receptor antagonist; IL6, interleukin-6; IL1 β , interleukin-1 β .

Table 4 Analysis of rate of decline of FEV₁ in the entire LHS cohort

Gene	Polymorphism	Genotype ^a	β (% predicted/year)	SE	P value
Rate of decline of pre-bronchodilator FEV₁					
<i>IL6</i>	rs2069825	CT/CT	–	–	–
		–/CT	0.0582	0.0356	0.1020
		–/–	–0.1130	0.0460	0.0141

Notes: ^aThe first allele is the major allele, the second is the minor allele.

Abbreviation: FEV₁, forced expiratory volume in 1 second; IL6, interleukin-6.

Analysis of cardiovascular disease and fatal cardiovascular disease

There was an association of the *IL6* polymorphism with cardiovascular disease, although there was only an effect of the heterozygous genotype ($P = 0.0446$). There was no association of the *IFNG* polymorphism or *IL1B-IL1RN* haplotypes with either cardiovascular disease outcome. In addition, we found a significant gene \times smoking interaction between cardiovascular disease and the *IL6* polymorphism ($P = 0.0239$, Table 6).

Discussion

We have investigated polymorphisms in the *IL6*, *IL1RN*, *IL1B*, and *IFNG* genes which have previously been demonstrated as risk factors for accelerated decline in lung function or baseline lung function in COPD patients. Unlike our previous

studies, which used nested case-control designs including patients within the extremes of distribution for lung function parameters, we only found an association for *IL6* with rate of decline in lung function for the entire LHS cohort. We found significant gene \times smoking interactions between *IL6* and *IFNG* and the rate of decline in lung function and baseline FEV₁, respectively. In addition, we also demonstrated a significant association between *IL6* and an *IL6* \times smoking interaction for cardiovascular disease.

The current paradigm for the pathogenesis of COPD includes a local and systemic inflammatory response to environmental challenges, notably cigarette smoking, which ultimately results in airflow obstruction. In COPD patients, high levels of serum or sputum IL6 have been associated with impaired lung function, exacerbations, pulmonary infections, and skeletal muscle weakness.^{22–27} It has also been

Table 5 Analysis of gene \times smoking interactions on lung function

Term	β	SE	P value
Rate of decline of pre-bronchodilator FEV₁			
Age	–0.0354	0.0038	<0.0001
BMI	0.0207	0.0066	0.0018
Smoking status [Continuous] ^a	–0.2521	0.0340	<0.0001
Mean cigarettes per day ^b	–0.0274	0.0030	<0.0001
<i>IL6</i> rs2069825 [–/–]	–0.0851	0.0344	0.0136
<i>IL6</i> rs2069825 [–/–] \times Mean cigarettes per day	–0.0071	0.0025	0.0044
Baseline level of pre-bronchodilator FEV₁			
Age	–0.1346	0.0229	<0.0001
BMI	–0.0926	0.0371	0.0125
Smoking history (pack-years)	–0.0354	0.0088	<0.0001
<i>IFNG</i> rs2069727 [A/G]	0.2841	0.1891	0.1331
<i>IFNG</i> rs2069727 [G/G]	–0.3918	0.2280	0.0858
<i>IFNG</i> rs2069727 [A/G] \times Smoking history	–0.0316	0.0126	0.0023
<i>IFNG</i> rs2069727 [G/G] \times Smoking history	0.0207	0.0158	0.0996
Baseline level of post-bronchodilator FEV₁			
Age	–0.2151	0.0236	<0.0001
BMI	–0.0142	0.0382	0.7102
Smoking history (pack-years)	–0.0445	0.0091	<0.0001
<i>IFNG</i> rs2069727 [A/G]	0.3225	0.1947	0.0977
<i>IFNG</i> rs2069727 [G/G]	–0.4193	0.2347	0.0742
<i>IFNG</i> rs2069727 [A/G] \times Smoking history	–0.0326	0.0107	0.0023
<i>IFNG</i> rs2069727 [G/G] \times Smoking history	0.0279	0.0129	0.0310

Notes: ^aNumber of packs of cigarettes smoked per day times number of years smoking; ^bNumber of cigarettes smoked per day during 5-year follow-up.

Abbreviations: BMI, body mass index; FEV₁, forced expiratory volume in 1 second; IL6, interleukin-6; IFN γ , interferon gamma.




Figure 1 *IL6* rs2069825 [-/-] genotype and rate of decline in lung function. Individuals in the Lung Health Study cohort were genotyped for the *IL6* rs2069825 single nucleotide polymorphism. Their genotype was plotted against mean cigarettes per day (x axis) and rate of decline (prebronchodilator FEV₁ [y axis]). The slopes demonstrate a faster decline in individuals with a [-/-] genotype (triangles) compared with individuals with the heterozygote [-C/C] or homozygote [C/C] genotypes (squares).

demonstrated that overexpression of *IL6* in the adult murine lung results in airway inflammation and emphysema-like airspace enlargement.²⁸ In this study, we found the *IL6* SNP rs2069825 deletion allele was associated with rate of decline of prebronchodilator FEV₁ in the entire LHS cohort. In a previous independent case-control sample study, associations of *IL6* SNPs with COPD susceptibility were also found. In particular, these *IL6* SNPs were in high linkage disequilibrium with the *IL6* SNP rs2069825 genotyped in the present study.⁵ *IL6* haplotypes, including rs2069825, have been previously associated with COPD in an independent study of a Caucasian population.²⁹ Furthermore, *IL6* haplotypes have been found to be associated with COPD defined by lung function in a Spanish population.³⁰ In contrast, a much

Table 6 Analysis of gene × smoking interactions on cardiovascular disease

Term	β	SE	P value
Gender [Male]	-0.3537	0.0524	<0.0001
Age	-0.0762	0.0074	<0.0001
BMI	-0.0330	0.0122	0.0069
Mean cigarettes per day ^a	-0.0001	0.0036	0.9664
Diastolic blood pressure at year 5	0.0261	0.0065	<0.0001
Systolic blood pressure at year 5	-0.0261	0.0039	<0.0001
<i>IL6</i> rs2069825 [-/CT]	0.1253	0.0624	0.0446
<i>IL6</i> rs2069825 [-/-]	-0.0475	0.0792	0.5489
<i>IL6</i> rs2069825 [-/CT] × mean cigarettes per day	-0.0101	0.0045	0.0239
<i>IL6</i> rs2069825 [-/-] × mean cigarettes per day	0.0010	0.0058	0.0873

Notes: ^aNumber of cigarettes smoked per day during 5-year follow-up.

Abbreviations: BMI, body mass index; *IL6*, interleukin-6.

smaller study has previously reported no association of an *IL6* SNP (rs1800795) with COPD.³¹ The rs1800795 polymorphism is in high linkage disequilibrium ($r^2 = 0.9$) with the *IL6* rs2069825 SNP investigated in this study. Because we believe that the associations found in well-powered cohorts are not likely to represent false positive results, together these studies indicate an association of *IL6* SNPs with COPD. In contrast with our previous study in which we analyzed the association of the *IL6* rs2069825 SNP with individuals not defined within the extremes of decline of lung function, we found no significant effect. However, when we analyzed the entire LHS cohort and the original subset of patients for rate of decline in prebronchodilator FEV₁, we did confirm the findings of our previous study.⁵ Our finding of an *IL6* rs2069825 interaction with level of smoking indicates that other factors are required for the effect of *IL6* rs2069825 to manifest. Indeed, this is the first study to demonstrate a gene × environment interaction for *IL6* and smoking with a lung function parameter.

The number of IFN γ -expressing lymphocytes is elevated in smokers and COPD bronchial biopsies.³² Studies of IFN γ knockout mice have also demonstrated an important role for IFN γ in emphysema.³³ The *IFNG* rs2069727 SNP was previously associated with baseline lung function in the LHS subset using the extremes of the distribution of lung function measurements.⁶ We also found a significant interaction with smoking history in our previous study.⁶ Therefore, the interaction of rs2069727 with pack-years of smoking in the total LHS cohort found in this study is consistent with these data. In support of the importance of *IFNG*, a different *IFNG* polymorphism (rs2430561) was previously associated with COPD in a Macedonian population.³⁴ For the *ILIRN* rs419598 and *IL1B* rs16944 polymorphisms, we found no associations with rate of decline or baseline FEV₁. We could confirm our findings of the previous association study for *ILIRN* and *IL1B* in the subset, but not the whole LHS cohort. This suggests that either the polymorphisms are only risk factors in the most severely affected individuals (those with very rapid decline in lung function), or the previous associations were false positive results.

It has long been recognized that smokers with COPD have high cardiovascular-related mortality.^{35,36} Indeed, decreased expiratory flow from the lung, which is the defining feature of COPD, increases the risk of ischemic heart disease, strokes, and sudden cardiac death by 2–3-fold, independent of other risk factors.³⁷ In particular, this increased risk is thought to be especially relevant to patients with mild to moderate COPD, because in severe

COPD patients the primary cause of death is usually respiratory disease.¹¹ The mechanisms of cardiovascular disease in COPD include hypoxia, systemic inflammation, and oxidative stress.³⁸ Due to the poor correlations of circulating levels of cytokines such as tumor necrosis factor and interleukin-8 with sputum levels in COPD, the data suggest that systemic inflammation may not be a simple spillover effect from lung inflammation.³⁹ Thus, intermediate factors may play an important role because smoking is associated with increased systemic levels of inflammatory mediators, including IL6, tumor necrosis factor, reactive oxygen species, and IFN γ .^{40,41} Although it is widely accepted that cigarette smoking induces systemic inflammation, which contributes to both the pathogenesis of COPD and cardiovascular disease morbidity and mortality,^{32,42} it is not known which inflammatory genes are important.

We found that the *IL6* rs2069825 SNP was associated with cardiovascular disease. The minor allele of the *IL6* promoter SNP, rs1800795 (-174G/C), has been previously associated with increased circulating IL6 levels, cardiovascular disease, and cardiovascular disease-related mortality in populations of older adults.⁴³⁻⁴⁶ However, *IL6* gene variation was only weakly associated with serum IL6 levels and not with cardiovascular outcomes in the Cardiovascular Health Study.⁴⁷ More recently, Carty et al studied several *IL6* SNPs in the Cardiovascular Health Study, including the *IL6* polymorphism, rs1554606,⁴⁸ which is in moderate linkage disequilibrium ($r^2 = 0.49$) with *IL6* rs2069825, the SNPs used in our study. However, the study found no associations between the five *IL6* SNPs investigated and cardiovascular outcomes.⁴⁸ The differences in the findings for *IL6* rs2069825 and cardiovascular disease outcome potentially reflects the cohorts studied. The Cardiovascular Health Study consisted of older patients (mean 72.6 years), of whom 59.5% were female and only 11.0% were current smokers⁴⁹ in comparison with our cohort, which consisted of only current smokers (on enrollment) with COPD that were 36.6% female and younger (mean 48.51 years).

The systemic inflammatory response is characterized by stimulation of the hematopoietic system. Circulating cytokines, such as IL6, have been postulated to stimulate the bone marrow to release leukocytes and platelets involved in systemic inflammation.⁵⁰ Several studies have shown increased levels of systemic IL6 in smokers compared with never-smokers.^{51,52} Furthermore, IL6 has been found to correlate significantly with fibrinogen and white blood cell counts,

reflecting a major role for IL6 as an inducer of fibrinogen,⁵³ which has been demonstrated to be an important marker in cardiovascular disease.⁵⁴ In addition, levels of IL6 can be used to predict future cardiovascular disease.^{17,55} Indeed, in COPD, IL6 levels are increased, particularly during exacerbations, and IL6 levels parallel C-reactive protein levels.⁵⁶

Our previous search for COPD susceptibility genes had focused on genes involved in the inflammatory response, but we had no intermediate phenotypes to test whether the significant associations we observed were acting through inflammatory pathways. The recent analysis of serum samples from the LHS participants offered the opportunity to use measurements of serum proteins and cytokines as powerful intermediate phenotypes. We examined the association of our identified SNPs with IL6, IFN γ , IL1 β , and IL1RN serum levels. We did not find any associations, and therefore we found no evidence that the associations we reported were mediated through an influence on the production of the serum cytokines measured. However, we did not measure cytokine levels within the lung, and therefore we could not test if the associations of *IL6* rs2069825 with lung function are driven via local pulmonary expression.

There are several explanations for the lack of association between the SNPs studied and serum cytokine levels measured. Many serum proteins have been demonstrated to have marked diurnal variability, and the serum samples were not obtained at a specific time of day for all patients. Additionally, the serum half-life of cytokines such as IL6 is short. Another limitation is the lack of healthy nonsmoking control subjects, thus the relationship of these candidate genes to normal lung function decline with age and cardiovascular disease in a nonsmoking population is unknown.

Compared with previous studies, the strengths of this study include a larger sample size and good power. This sample size provides more than adequate power to detect common genetic risk variants, as shown in our previous power analyses.⁵⁷ There were several potential limitations to the study. First, false positive results could have been generated by population stratification. However, previous studies have suggested that US Caucasian populations are unlikely to contain sufficient stratification to cause widespread false positive results.⁵⁸ One important difference with our previously identified associations between IL6, IFN γ , IL1 β , and IL1RN polymorphisms and rate of decline and baseline lung function is that these studies utilized a case-control analysis that compared individuals from the

extremes of the distribution for rate of decline or baseline lung function. When we analyzed the entire LHS cohort, only the *IL6* rs2069825 SNP remained significant. This could indicate that the *IFNG* rs2069727, *IL1RN* rs419598, and *IL1B* rs16944 polymorphisms previously identified are important only in individuals with severe airflow limitation and rapid decline in lung function over the course of their disease. There may also be increased power to detect genetic susceptibility loci using extremes of the distribution of a continuous variable.⁵⁹ However, it is also possible that previous studies were underpowered and the results obtained were false positives.

In this study, we have made multiple comparisons and therefore most of the results would not be significant at the 5% level if a Bonferroni correction was made. On the other hand, only a limited number of SNPs were chosen based on a prior association with lung function measures in the LHS. Furthermore, the prebronchodilator and postbronchodilator measures of lung function utilized in this study are highly correlated. Only the association of the *IL6* rs2069825 SNP with mean number of cigarettes smoked per day on rate of decline of prebronchodilator FEV₁ was significant after correction for multiple comparisons. Thus, given the lack of formal significance for the other reported results, they should be regarded as hypothesis-generating.

In summary, we have demonstrated significant interactions of the *IL6* rs2069825 and *IFNG* rs2069727 SNPs with cigarette smoking on lung function in a well-powered cohort of exsmokers and current smokers. In addition, the *IL6* rs2069825 SNP was also associated with cardiovascular disease. Because several large randomized clinical trials and population-based studies have demonstrated a substantial reduction in the risk of cardiovascular disease and loss of lung function following smoking cessation.^{60–62} We propose that individuals with the *IL6* rs2069825 SNP would be at risk for the development of both COPD and cardiovascular disease, and could be targeted in future therapeutic strategies aimed at the *IL6* pathway.

Acknowledgments

This work was supported by grants from the Canadian Institutes of Health Research and National Institutes of Health. The Lung Health Study was supported by the Division of Lung Diseases of the National Heart, Lung, and Blood Institute. TLH is a recipient of CIHR/Canadian Lung Association/GSK, CIHR IMPACT, and Michael Smith Foundation for Health Research

post-doctoral fellowships. AS is the recipient of a Canada Research Chair in genetics and a Michael Smith Foundation for Health Research senior scholar award.

Disclosure

The authors have no conflicts of interest to report in this work.

References

- Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. *Lancet*. 2003;362(9387):847–852.
- Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: A case-control study. *Lancet*. 2006;368(9536):647–658.
- Garantziotis S, Schwartz DA. Ecogenomics of respiratory diseases of public health significance. *Annu Rev Public Health*. 2010;31:37–51.
- Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. *Eur Respir J*. 2009;33(5):1165–1185.
- He JQ, Foreman MG, Shumansky K, et al. Associations of *IL6* polymorphisms with lung function decline and COPD. *Thorax*. 2009;64(8):698–704.
- He JQ, Burkett K, Connett JE, Anthonisen NR, Paré PD, Sandford AJ. Interferon gamma polymorphisms and their interaction with smoking are associated with lung function. *Hum Genet*. 2006;119(4):365–375.
- Joos L, McIntyre L, Ruan J, et al. Association of *IL-1beta* and *IL-1* receptor antagonist haplotypes with rate of decline in lung function in smokers. *Thorax*. 2001;56(11):863–866.
- Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV₁. The Lung Health Study. *JAMA*. 1994;272(19):1497–1505.
- Enright PL, Connett JE, Kanner RE, Johnson LR, Lee WW. Spirometry in the Lung Health Study. 1. Methods and quality control. *Am Rev Respir Dis*. 1991;143(6):1215–1223.
- American Thoracic Society. Standardization of spirometry – 1987 update. Statement of the American Thoracic Society. *Am Rev Respir Dis*. 1987;136(5):1285–1298.
- Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: A randomized clinical trial. *Ann Intern Med*. 2005;142(4):233–239.
- Jha HC, Divya A, Prasad J, Mittal A. Plasma circulatory markers in male and female patients with coronary artery disease. *Heart Lung*. 2010;39(4):296–303.
- Isoda K, Ohsuzu F. The effect of interleukin-1 receptor antagonist on arteries and cholesterol metabolism. *J Atheroscler Thromb*. 2006;13(1):21–30.
- Guillén I, Blanes M, Gómez-Lechón MJ, Castell JV. Cytokine signaling during myocardial infarction: Sequential appearance of *IL-1 beta* and *IL-6*. *Am J Physiol*. 1995;269(2 Pt 2):R229–R235.
- Patti G, D'Ambrosio A, Mega S, et al. Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. *J Am Coll Cardiol*. 2004;43(1):35–38.
- Miyao Y, Yasue H, Ogawa H, et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. *Am Heart J*. 1993;126(6):1299–1304.
- Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). *Am J Cardiol*. 2003;92(5):522–528.
- Gaunt TR, Rodriguez S, Day IN. Cubic exact solutions for the estimation of pairwise haplotype frequencies: Implications for linkage disequilibrium analyses and a web tool 'CubeX'. *BMC Bioinformatics*. 2007;8:428.
- Carter KW, McCaskie PA, Palmer LJ. SimHap GUI: An intuitive graphical user interface for genetic association analysis. *BMC Bioinformatics*. 2008;9:557.

20. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. *Am J Hum Genet.* 2004;74(4):765–769.
21. Clay FE, Tarlow JK, Cork MJ, Cox A, Nicklin MJ, Duff GW. Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment. *Hum Genet.* 1996;97(6):723–726.
22. De Torres JP, Pinto-Plata V, Casanova C, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. *Chest.* 2008;133(6):1336–1343.
23. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2006;173(1):71–78.
24. Hurst JR, Donaldson GC, Perera WR. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2006;174(8):867–874.
25. Wilkinson TM, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. *Chest.* 2006;129(2):317–324.
26. Yende S, Waterer GW, Tolley EA, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. *Thorax.* 2006;61(1):10–16.
27. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. *Thorax.* 2006;61(1):17–22.
28. Kuhn C 3rd, Homer RJ, Zhu Z, et al. Airway hyperresponsiveness and airway obstruction in transgenic mice. Morphologic correlates in mice overexpressing interleukin (IL)-11 and IL-6 in the lung. *Am J Respir Cell Mol Biol.* 2000;22(3):289–295.
29. Yanbaeva DG, Dentener MA, Spruit MA, et al. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: A case-control study. *BMC Med Genet.* 2009;10:23.
30. Córdoba-Lanús E, de-Torres JP, López-Aguilar C, et al. Association of IL-6 gene polymorphisms and COPD in a Spanish population. *Respir Med.* 2008;102(12):1805–1811.
31. Seifart C, Dempfle A, Plagens A, et al. TNF-alpha-, TNF-beta-, IL-6-, and IL-10-promoter polymorphisms in patients with chronic obstructive pulmonary disease. *Tissue Antigens.* 2005;65(1):93–100.
32. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. *Lancet.* 2004;364(9435):709–721.
33. Wang Z, Zheng T, Zhu Z, et al. Interferon gamma induction of pulmonary emphysema in the adult murine lung. *J Exp Med.* 2000;192(11):1587–1600.
34. Trajkov D, Mirkovska-Stojkovic J, Petlichkovski A, et al. Association of cytokine gene polymorphisms with chronic obstructive pulmonary disease in Macedonians. *Iran J Allergy Asthma Immunol.* 2009;8(1):31–42.
35. Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. *Am J Respir Crit Care Med.* 2002;166(3):333–339.
36. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med.* 2007;356(8):775–789.
37. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: A population-based study and a systematic review of the literature. *Chest.* 2005;127(6):1952–1959.
38. McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnea: Overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. *Am J Respir Crit Care Med.* 2009;180(8):692–700.
39. Vernooij JH, Küçükaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: Soluble tumor necrosis factor receptors are increased in sputum. *Am J Respir Crit Care Med.* 2002;166(9):1218–1224.
40. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. *Chest.* 2007;131(5):1557–1566.
41. Brozyna S, Ahern J, Hodge G, et al. Chemotactic mediators of Th1 T-cell trafficking in smokers and COPD patients. *COPD.* 2009;6(1):4–16.
42. MacCallum PK. Markers of hemostasis and systemic inflammation in heart disease and atherosclerosis in smokers. *Proc Am Thorac Soc.* 2005;2(1):34–43.
43. Mayosi BM, Avery PJ, Baker M, et al. Genotype at the -174G/C polymorphism of the interleukin-6 gene is associated with common carotid artery intimal-medial thickness: family study and meta-analysis. *Stroke.* 2005;36(10):2215–2219.
44. Brull DJ, Montgomery HE, Sanders J, et al. Interleukin-6 gene -174 g > c and -572 g > c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. *Arterioscler Thromb Vasc Biol.* 2001;21(9):1458–1463.
45. Podgoreanu MV, Schwinn DA. New paradigms in cardiovascular medicine: Emerging technologies and practices: Perioperative genomics. *J Am Coll Cardiol.* 2005;46(11):1965–1977.
46. Jenny NS, Tracy RP, Ogg MS, et al. In the elderly, interleukin-6 plasma levels and the -174G > C polymorphism are associated with the development of cardiovascular disease. *Arterioscler Thromb Vasc Biol.* 2002;22(12):2066–2071.
47. Walston JD, Fallin MD, Cushman M, et al. IL-6 gene variation is associated with IL-6 and C-reactive protein levels but not cardiovascular outcomes in the Cardiovascular Health Study. *Hum Genet.* 2007;122(5):485–494.
48. Carty CL, Heagerty P, Heckbert SR, et al. Interaction between fibrinogen and IL-6 genetic variants and associations with cardiovascular disease risk in the Cardiovascular Health Study. *Ann Hum Genet.* 2010;74(1):1–10.
49. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: Design and rationale. *Ann Epidemiol.* 1991;1(3):263–276.
50. van Eeden SF, Yeung A, Quinlan K, Hogg JC. Systemic response to ambient particulate matter: Relevance to chronic obstructive pulmonary disease. *Proc Am Thorac Soc.* 2005;2(1):61–67.
51. Helmersson J, Larsson A, Vessby B, Basu S. Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. *Atherosclerosis.* 2005;181(1):201–207.
52. Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM. Relation between markers of systemic vascular inflammation and smoking in women. *Am J Cardiol.* 2002;89(9):1117–1119.
53. Woodward M, Rumley A, Tunstall-Pedoe H, Lowe GD. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. *Br J Haematol.* 1999;104(2):246–257.
54. Kamath S, Lip GY. Fibrinogen: Biochemistry, epidemiology and determinants. *QJM.* 2003;96(10):711–729.
55. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. *Circulation.* 2000;101(15):1767–1772.
56. Walter RE, Wilk JB, Larson MG, et al. Systemic inflammation and COPD: The Framingham Heart Study. *Chest.* 2008;133(1):19–25.
57. Tanaka G, Sandford AJ, Burkett K, et al. Tumour necrosis factor and lymphotoxin A polymorphisms and lung function in smokers. *Eur Respir J.* 2007;29(1):34–41.
58. Ardlie KG, Lunetta KL, Seielstad M. Testing for population subdivision and association in four case-control studies. *Am J Hum Genet.* 2002;71(2):304–311.
59. Allison DB, Heo M, Schork NJ, Wong SL, Elston RC. Extreme selection strategies in gene mapping studies of oligogenic quantitative traits do not always increase power. *Hum Hered.* 1998;48(2):97–107.
60. Twardella D, Küpper-Nybelen J, Rothenbacher D, Hahmann H, Wüsten B, Brenner H. Short-term benefit of smoking cessation in patients with coronary heart disease: Estimates based on self-reported smoking data and serum cotinine measurements. *Eur Heart J.* 2004;25(23):2101–2108.

61. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. *Cochrane Database Syst Rev.* 2004;1: CD003041.
62. Gratiou C. Respiratory, cardiovascular and other physiological consequences of smoking cessation. *Curr Med Res Opin.* 2009;25(2): 535–545.

International Journal of COPD

Dovepress

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-copd-journal>

This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.